Integrated approaches for genome-wide interrogation of the druggable non-olfactory G protein-coupled receptor superfamily

Journal of Biological Chemistry

Volumn 290, Issue 32, 2015, Pages 19471-19477

  Roth, Bryan L ^a   Kroeze, Wesley K ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MEMBRANES; GENES;

DRUG DISCOVERY; G PROTEIN COUPLED RECEPTORS; HUMAN GENOMES; INTEGRATED APPROACH; SIDE EFFECT;

PROTEINS;

ALBIGLUTIDE; DROXIDOPA; DULAGLUTIDE; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; NALOXEGOL; NETUPITANT PLUS PALONOSETRON; OLODATEROL; SEROTONIN 2 RECEPTOR; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN; SUVOREXANT; TASIMELTEON; VORAPAXAR; LIGAND; MOLECULAR LIBRARY; NEW DRUG; PROTEIN BINDING; PROTEOME;

BIOINFORMATICS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONSTIPATION; DRUG DATABASE; DRUG INDICATION; DRUG SCREENING; DRUG TARGETING; HUMAN; HUMAN GENOME; INSOMNIA; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PROTEIN FAMILY; SHORT SURVEY; SLEEP DISORDER; THORAX PAIN; AGONISTS; ANTAGONISTS AND INHIBITORS; BIBLIOGRAPHIC DATABASE; BINDING SITE; CHEMICAL DATABASE; CHEMISTRY; GENETICS; METABOLISM; MOLECULAR LIBRARY; PHARMACOLOGY; SYNTHESIS;

BINDING SITES; DATABASES, BIBLIOGRAPHIC; DATABASES, CHEMICAL; DATABASES, PHARMACEUTICAL; DRUGS, INVESTIGATIONAL; GENOME, HUMAN; HUMANS; LIGANDS; PROTEIN BINDING; PROTEOME; RECEPTORS, G-PROTEIN-COUPLED; SMALL MOLECULE LIBRARIES;

EID: 84939151970     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.R115.654764     Document Type: Short Survey

References (74)

1. Hopkins, A. L., and Groom, C. R. (2002) The druggable genome. Nat. Rev. Drug. Discov. 1, 727-730
2. Overington, J. P., Al-Lazikani, B., and Hopkins, A. L. (2006) How many drug targets are there? Nat. Rev. Drug. Discov. 5, 993-996
3. Keiser, M. J., Setola, V., Irwin, J. J., Laggner, C., Abbas, A. I., Hufeisen, S. J., Jensen, N. H., Kuijer, M. B., Matos, R. C., Tran, T. B., Whaley, R., Glennon, R. A., Hert, J., Thomas, K. L., Edwards, D. D., Shoichet, B. K., and Roth, B. L. (2009) Predicting new molecular targets for known drugs. Nature 462, 175-181
4. Rask-Andersen, M., Almén, M. S., and Schiöth, H. B. (2011) Trends in the exploitation of novel drug targets. Nat. Rev. Drug. Discov. 10, 579-590
5. Shapiro, D. A., Renock, S., Arrington, E., Chiodo, L. A., Liu, L. X., Sibley, D. R., Roth, B. L., and Mailman, R. (2003) Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28, 1400-1411
6. Rothman, R. B., Baumann, M. H., Savage, J. E., Rauser, L., McBride, A., Hufeisen, S. J., and Roth, B. L. (2000) Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102, 2836-2841
7. Setola, V., Hufeisen, S. J., Grande-Allen, K. J., Vesely, I., Glennon, R. A., Blough, B., Rothman, R. B., and Roth, B. L. (2003) 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol. Pharmacol. 63, 1223-1229
8. Roth, B. L. (2007) Drugs and valvular heart disease. N. Engl. J. Med. 356, 6-9
9. Zanettini, R., Antonini, A., Gatto, G., Gentile, R., Tesei, S., and Pezzoli, G. (2007) Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N. Engl. J. Med. 356, 39-46
10. Huang, X. P., Setola, V., Yadav, P. N., Allen, J. A., Rogan, S. C., Hanson, B. J., Revankar, C., Robers, M., Doucette, C., and Roth, B. L. (2009) Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine2B receptor agonists: implications for drug safety assessment. Mol. Pharmacol. 76, 710-722
11. Wacker, D., Wang, C., Katritch, V., Han, G. W., Huang, X. P., Vardy, E., McCorvy, J. D., Jiang, Y., Chu, M., Siu, F. Y., Liu, W., Xu, H. E., Cherezov, V., Roth, B. L., and Stevens, R. C. (2013) Structural features for functional selectivity at serotonin receptors. Science 340, 615-619
12. Vickers, S. P., Clifton, P. G., Dourish, C. T., and Tecott, L. H. (1999) Reduced satiating effect of D-fenfluramine in serotonin 5-HT2C receptor mutant mice. Psychopharmacology 143, 309-314
13. O'Connor, K. A., and Roth, B. L. (2005) Finding new tricks for old drugs: an efficient route for public-sector drug discovery. Nat. Rev. Drug. Discov. 4, 1005-1014
14. Meltzer, H. Y., and Roth, B. L. (2013) Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype-targeted drugs. J. Clin. Invest. 123, 4986-4991
15. Thomsen, W. J., Grottick, A. J., Menzaghi, F., Reyes-Saldana, H., Espitia, S., Yuskin, D., Whelan, K., Martin, M., Morgan, M., Chen, W., Al- Shamma, H., Smith, B., Chalmers, D., and Behan, D. (2008) Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization. J. Pharmacol. Exp. Ther. 325, 577-587
16. Smith, S. R., Weissman, N. J., Anderson, C. M., Sanchez, M., Chuang, E., Stubbe, S., Bays, H., Shanahan, W. R., and the Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group (2010) Multicenter, placebo-controlled trial of lorcaserin for weight management. N. Engl. J. Med. 363, 245-256
17. Allen, J. A., and Roth, B. L. (2011) Strategies to discover unexpected targets for drugs active at G protein-coupled receptors. Annu. Rev. Pharmacol. Toxicol. 51, 117-144
18. Wootten, D., Christopoulos, A., and Sexton, P. M. (2013) Emerging paradigms in GPCR allostery: implications for drug discovery. Nat. Rev. Drug. Discov. 12, 630-644
19. Violin, J. D., Crombie, A. L., Soergel, D. G., and Lark, M. W. (2014) Biased ligands at G-protein-coupled receptors: promise and progress. Trends Pharmacol. Sci. 35, 308-316
20. Keiser, M. J., Roth, B. L., Armbruster, B. N., Ernsberger, P., Irwin, J. J., and Shoichet, B. K. (2007) Relating protein pharmacology by ligand chemistry. Nat. Biotechnol. 25, 197-206
21. Lounkine, E., Keiser, M. J., Whitebread, S., Mikhailov, D., Hamon, J., Jenkins, J. L., Lavan, P., Weber, E., Doak, A. K., Côté, S., Shoichet, B. K., and Urban, L. (2012) Large-scale prediction and testing of drug activity on side-effect targets. Nature 486, 361-367
22. Besnard, J., Ruda, G. F., Setola, V., Abecassis, K., Rodriguiz, R. M., Huang, X. P., Norval, S., Sassano, M. F., Shin, A. I., Webster, L. A., Simeons, F. R., Stojanovski, L., Prat, A., Seidah, N. G., Constam, D. B., Bickerton, G. R., Read, K. D., Wetsel, W. C., Gilbert, I. H., Roth, B. L., and Hopkins, A. L. (2012) Automated design of ligands to polypharmacological profiles. Nature 492, 215-220
23. Lemieux, G. A., Keiser, M. J., Sassano, M. F., Laggner, C., Mayer, F., Bainton, R. J., Werb, Z., Roth, B. L., Shoichet, B. K., and Ashrafi, K. (2013) In silico molecular comparisons of C. elegans and mammalian pharmacology identify distinct targets that regulate feeding. PLoS Biol. 11, e1001712
24. Laggner, C., Kokel, D., Setola, V., Tolia, A., Lin, H., Irwin, J. J., Keiser, M. J., Cheung, C. Y., Minor, D. L., Jr., Roth, B. L., Peterson, R. T., and Shoichet, B. K. (2012) Chemical informatics and target identification in a zebrafish phenotypic screen. Nat. Chem. Biol. 8, 144-146
25. Wang, J., Simonavicius, N., Wu, X., Swaminath, G., Reagan, J., Tian, H., and Ling, L. (2006) Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J. Biol. Chem. 281, 22021-22028
26. Jenkins, L., Alvarez-Curto, E., Campbell, K., de Munnik, S., Canals, M., Schlyer, S., and Milligan, G. (2011) Agonist activation of the G protein-coupled receptor GPR35 involves transmembrane domain III and is transduced via Gα13 and β-arrestin-2. Br. J. Pharmacol. 162, 733-748
27. Edwards, A. M., Isserlin, R., Bader, G. D., Frye, S. V., Willson, T. M., and Yu, F. H. (2011) Too many roads not taken. Nature 470, 163-165
28. Isserlin, R., Bader, G. D., A., E., Frye, S., Willson, T., and Yu, F. (2011) The human genome and drug discovery after a decade: roads (still) not taken. arXiv:1102.0448
29. Kotsikorou, E., Sharir, H., Shore, D. M., Hurst, D. P., Lynch, D. L., Madrigal, K. E., Heynen-Genel, S., Milan, L. B., Chung, T. D., Seltzman, H. H., Bai, Y., Caron, M. G., Barak, L. S., Croatt, M. P., Abood, M. E., and Reggio, P. H. (2013) Identification of the GPR55 antagonist binding site using a novel set of high-potency GPR55 selective ligands. Biochemistry 52, 9456-9469
30. Kotsikorou, E., Madrigal, K. E., Hurst, D. P., Sharir, H., Lynch, D. L., Heynen-Genel, S., Milan, L. B., Chung, T. D., Seltzman, H. H., Bai, Y., Caron, M. G., Barak, L., Abood, M. E., and Reggio, P. H. (2011) Identification of the GPR55 agonist binding site using a novel set of high-potency GPR55 selective ligands. Biochemistry 50, 5633-5647
31. Zhao, P., Sharir, H., Kapur, A., Cowan, A., Geller, E. B., Adler, M. W., Seltzman, H. H., Reggio, P. H., Heynen-Genel, S., Sauer, M., Chung, T. D., Bai, Y., Chen, W., Caron, M. G., Barak, L. S., and Abood, M. E. (2010) Targeting of the orphan receptor GPR35 by pamoic acid: a potent activator of extracellular signal-regulated kinase and β-arrestin2 with antinociceptive activity. Mol. Pharmacol. 78, 560-568
32. Armbruster, B. N., and Roth, B. L. (2005) Mining the receptorome. J. Biol. Chem. 280, 5129-5132
33. Jensen, N. H., and Roth, B. L. (2008) Massively parallel screening of the receptorome. Comb. Chem. High Throughput Screen. 11, 420-426
34. Strachan, R. T., Ferrara, G., and Roth, B. L. (2006) Screening the receptorome: an efficient approach for drug discovery and target validation. Drug Discov. Today 11, 708-716
35. Roth, B. L., Baner, K., Westkaemper, R., Siebert, D., Rice, K. C., Steinberg, S., Ernsberger, P., and Rothman, R. B. (2002) Salvinorin A: a potent naturally occurring nonnitrogenous κ-opioid selective agonist. Proc. Natl. Acad. Sci. U.S.A. 99, 11934-11939
36. Roth, B. L., Sheffler, D. J., and Kroeze, W. K. (2004) Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat. Rev. Drug. Discov. 3, 353-359
37. Lin, X., Huang, X. P., Chen, G., Whaley, R., Peng, S., Wang, Y., Zhang, G., Wang, S. X., Wang, S., Roth, B. L., and Huang, N. (2012) Life beyond kinases: structure-based discovery of sorafenib as nanomolar antagonist of 5-HT receptors. J. Med. Chem. 55, 5749-5759
38. Lin, H., Sassano, M. F., Roth, B. L., and Shoichet, B. K. (2013) A pharmacological organization of G protein-coupled receptors. Nat. Methods 10, 140-146
39. Gregori-Puigjané, E., Setola, V., Hert, J., Crews, B. A., Irwin, J. J., Lounkine, E., Marnett, L., Roth, B. L., and Shoichet, B. K. (2012) Identifying mechanism-of-action targets for drugs and probes. Proc. Natl. Acad. Sci. U.S.A. 109, 11178-11183
40. Carlsson, J., Coleman, R. G., Setola, V., Irwin, J. J., Fan, H., Schlessinger, A., Sali, A., Roth, B. L., and Shoichet, B. K. (2011) Ligand discovery from a dopamine D3 receptor homology model and crystal structure. Nat. Chem. Biol. 7, 769-778
41. Weiss, D. R., Ahn, S., Sassano, M. F., Kleist, A., Zhu, X., Strachan, R., Roth, B. L., Lefkowitz, R. J., and Shoichet, B. K. (2013) Conformation guides molecular efficacy in docking screens of activated ô-2 adrenergic G protein coupled receptor. ACS Chem. Biol. 8, 1018-1026
42. Wang, C., Wu, H., Evron, T., Vardy, E., Han, G. W., Huang, X. P., Hufeisen, S. J., Mangano, T. J., Urban, D. J., Katritch, V., Cherezov, V., Caron, M. G., Roth, B. L., and Stevens, R. C. (2014) Structural basis for Smoothened receptor modulation and chemoresistance to anticancer drugs. Nat. Commun. 5, 4355
43. Wu, H., Wacker, D., Mileni, M., Katritch, V., Han, G. W., Vardy, E., Liu, W., Thompson, A. A., Huang, X. P., Carroll, F. I., Mascarella, S. W., Westkaemper, R. B., Mosier, P. D., Roth, B. L., Cherezov, V., and Stevens, R. C. (2012) Structure of the human κ-opioid receptor in complex with JDTic. Nature 485, 327-332
44. Wang, C., Wu, H., Katritch, V., Han, G. W., Huang, X. P., Liu, W., Siu, F. Y., Roth, B. L., Cherezov, V., and Stevens, R. C. (2013) Structure of the human smoothened receptor bound to an antitumour agent. Nature 497, 338-343
45. Wang, C., Jiang, Y., Ma, J., Wu, H., Wacker, D., Katritch, V., Han, G. W., Liu, W., Huang, X. P., Vardy, E., McCorvy, J. D., Gao, X., Zhou, X. E., Melcher, K., Zhang, C., Bai, F., Yang, H., Yang, L., Jiang, H., Roth, B. L., Cherezov, V., Stevens, R. C., and Xu, H. E. (2013) Structural basis for molecular recognition at serotonin receptors. Science 340, 610-614
46. Vardy, E., Mosier, P. D., Frankowski, K. J., Wu, H., Katritch, V., Westkaemper, R. B., Aubé, J., Stevens, R. C., and Roth, B. L. (2013) Chemotype-selective modes of action of κ-opioid receptor agonists. J. Biol. Chem. 288, 34470-34483
47. Kroeze, W. K., Sassano, M. F., Huang, X. P., Lansu, K., McCorvy, J. D., Giguère, P. M., Sciaky, N., and Roth, B. L. (2015) PRESTO-Tango as an open-source resource for interrogation of the druggable human GPCR-ome. Nat. Struct. Mol. Biol. 22, 362-369
48. Thompson, A. A., Liu, W., Chun, E., Katritch, V., Wu, H., Vardy, E., Huang, X. P., Trapella, C., Guerrini, R., Calo, G., Roth, B. L., Cherezov, V., and Stevens, R. C. (2012) Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic. Nature 485, 395-399
49. Coward, P., Chan, S. D., Wada, H. G., Humphries, G. M., and Conklin, B. R. (1999) Chimeric G proteins allow a high-throughput signaling assay of Gi-coupled receptors. Anal. Biochem. 270, 242-248
50. Coward, P., Wada, H. G., Falk, M. S., Chan, S. D., Meng, F., Akil, H., and Conklin, B. R. (1998) Controlling signaling with a specifically designed Gi-coupled receptor. Proc. Natl. Acad. Sci. U.S.A. 95, 352-357
51. Beets, I., Lindemans, M., Janssen, T., and Verleyen, P. (2011) Deorphanizing G protein-coupled receptors by a calcium mobilization assay. Methods Mol. Biol. 789, 377-391
52. Jin, C., Decker, A. M., Huang, X. P., Gilmour, B. P., Blough, B. E., Roth, B. L., Hu, Y., Gill, J. B., and Zhang, X. P. (2014) Synthesis, pharmacological characterization, and structure-activity relationship studies of small molecular agonists for the orphan GPR88 receptor. ACS Chem. Neurosci. 5, 576-587
53. Inoue, A., Ishiguro, J., Kitamura, H., Arima, N., Okutani, M., Shuto, A., Higashiyama, S., Ohwada, T., Arai, H., Makide, K., and Aoki, J. (2012) TGFα shedding assay: an accurate and versatile method for detecting GPCR activation. Nat. Methods 9, 1021-1029
54. Lefkowitz, R. J., and Shenoy, S. K. (2005) Transduction of receptor signals by β-arrestins. Science 308, 512-517
55. Barak, L. S., Warabi, K., Feng, X., Caron, M. G., and Kwatra, M. M. (1999) Real-time visualization of the cellular redistribution of G protein-coupled receptor kinase 2 and β-arrestin 2 during homologous desensitization of the substance P receptor. J. Biol. Chem. 274, 7565-7569
56. Angers, S., Salahpour, A., Joly, E., Hilairet, S., Chelsky, D., Dennis, M., and Bouvier, M. (2000) Detection of β2-adrenergic receptor dimerization in living cells using bioluminescence resonance energy transfer (BRET). Proc. Natl. Acad. Sci. U.S.A. 97, 3684-3689
57. Barnea, G., Strapps, W., Herrada, G., Berman, Y., Ong, J., Kloss, B., Axel, R., and Lee, K. J. (2008) The genetic design of signaling cascades to record receptor activation. Proc. Natl. Acad. Sci. U.S.A. 105, 64-69
58. White, K. L., Scopton, A. P., Rives, M. L., Bikbulatov, R. V., Polepally, P. R., Brown, P. J., Kenakin, T., Javitch, J. A., Zjawiony, J. K., and Roth, B. L. (2014) Identification of novel functionally selective κ-opioid receptor scaffolds. Mol. Pharmacol. 85, 83-90
59. Fenalti, G., Giguere, P. M., Katritch, V., Huang, X. P., Thompson, A. A., Cherezov, V., Roth, B. L., and Stevens, R. C. (2014) Molecular control of δ-opioid receptor signalling. Nature 506, 191-196
60. Rajaratnam, S. M., Polymeropoulos, M. H., Fisher, D. M., Roth, T., Scott, C., Birznieks, G., and Klerman, E. B. (2009) Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials. Lancet 373, 482-491
61. Bartholini, J., Constantinidis, J., Puig, M., Tissot, R., and Pletscher, A. (1975) The stereoisomers of 3,4-dihydroxyphenylserine as precursors of norepinephrine. J. Pharmacol. Exp. Ther. 193, 523-532
62. Kaufmann, H., Freeman, R., Biaggioni, I., Low, P., Pedder, S., Hewitt, L. A., Mauney, J., Feirtag, M., and Mathias, C., on behalf of NOH301 Investigators (2014) Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial. Neurology 83, 328-335
63. Bush, M. A., Matthews, J. E., De Boever, E. H., Dobbins, R. L., Hodge, R. J., Walker, S. E., Holland, M. C., Gutierrez, M., and Stewart, M. W. (2009) Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects. Diabetes Obes. Metab. 11, 498-505
64. Matthews, J. E., Stewart, M. W., De Boever, E. H., Dobbins, R. L., Hodge, R. J., Walker, S. E., Holland, M. C., Bush, M. A., and the Albiglutide Study Group (2008) Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 93, 4810-4817
65. Becker, R. C., Moliterno, D. J., Jennings, L. K., Pieper, K. S., Pei, J., Niederman, A., Ziada, K. M., Berman, G., Strony, J., Joseph, D., Mahaffey, K. W., Van de Werf, F., Veltri, E., Harrington, R. A., and TRA-PCI Investigators (2009) Safety and tolerability of SCH 530348 in patients undergoing nonurgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet 373, 919-928
66. Bouyssou, T., Casarosa, P., Naline, E., Pestel, S., Konetzki, I., Devillier, P., and Schnapp, A. (2010) Pharmacological characterization of olodaterol, a novel inhaled β2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models. J. Pharmacol. Exp. Ther. 334, 53-62
67. Cox, C. D., Breslin, M. J., Whitman, D. B., Schreier, J. D., McGaughey, G. B., Bogusky, M. J., Roecker, A. J., Mercer, S. P., Bednar, R. A., Lemaire, W., Bruno, J. G., Reiss, D. R., Harrell, C. M., Murphy, K. L., Garson, S. L., Doran, S. M., Prueksaritanont, T., Anderson, W. B., Tang, C., Roller, S., Cabalu, T. D., Cui, D., Hartman, G. D., Young, S. D., Koblan, K. S., Winrow, C. J., Renger, J. J., and Coleman, P. J. (2010) Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl] methanone (MK-4305) for the treatment of insomnia. J. Med. Chem. 53, 5320-5332
68. Chey, W. D., Webster, L., Sostek, M., Lappalainen, J., Barker, P. N., and Tack, J. (2014) Naloxegol for opioid-induced constipation in patients with noncancer pain. N. Engl. J. Med. 370, 2387-2396
69. Glaesner, W., Vick, A. M., Millican, R., Ellis, B., Tschang, S. H., Tian, Y., Bokvist, K., Brenner, M., Koester, A., Porksen, N., Etgen, G., and Bumol, T. (2010) Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes Metab. Res. Rev. 26, 287-296
70. Gralla, R. J., Bosnjak, S. M., Hontsa, A., Balser, C., Rizzi, G., Rossi, G., Borroni, M. E., and Jordan, K. (2014) A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann. Oncol. 25, 1333-1339
71. Gaulton, A., Bellis, L. J., Bento, A. P., Chambers, J., Davies, M., Hersey, A., Light, Y., McGlinchey, S., Michalovich, D., Al-Lazikani, B., and Overington, J. P. (2012) ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res. 40, D1100-1107
72. Roth, B. L., Lopez, E., Patel, S., and Kroeze, W. K. (2000) The multiplicity of serotonin receptors: uselessly diverse molecules or an embarrassment of riches? Neuroscientist 6, 252-262, 10.1177/107385840000600408
73. Seiler, K. P., George, G. A., Happ, M. P., Bodycombe, N. E., Carrinski, H. A., Norton, S., Brudz, S., Sullivan, J. P., Muhlich, J., Serrano, M., Ferraiolo, P., Tolliday, N. J., Schreiber, S. L., and Clemons, P. A. (2008) Chem-Bank: a small-molecule screening and cheminformatics resource database. Nucleic Acids Res. 36, D351-359
74. Wang, Y., Xiao, J., Suzek, T. O., Zhang, J., Wang, J., and Bryant, S. H. (2009) PubChem: a public information system for analyzing bioactivities of small molecules. Nucleic Acids Res. 37, W623-633